Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

Published:2004-02 Issue:2 Volume:63 Page:127-134
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Jovanovic Lois,Hassman David R,Gooch Brent,Jain Rajeev,Greco Susan,Khutoryansky Naum,Hale Paula M

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference17 articles.

1. American Diabetes Association, Implications of the United Kingdom Prospective Diabetes Study, Diabetes Care 25(Suppl. 1) (2002) S28–S32.

2. UK Prospective Diabetes Study Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837–853.

3. UK Prospective Diabetes Study Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet 352 (1998) 854–865.

4. Oral agents in the management of type 2 diabetes mellitus;Luna;Am. Fam. Physician,2001

5. Repaglinide (Prandin) product labeling, 2003.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatic Gland Therapies;Endocrinology;2023-12-15

2. Polysaccharides (pectin, mucilage, and fructan inulin) and their fermented products: A critical analysis of their biochemical, gut interactions, and biological functions as antidiabetic agents;Phytotherapy Research;2023-11-15

3. To the assessment of the use of sugar-reducing drugs from the position of safety;Patient-Oriented Medicine and Pharmacy;2023-02-21

4. Efficacy and Cardiovascular Safety of Meglitinides;Current Drug Safety;2021-06-08

5. Structure – Activity Relationship and Therapeutic Benefits of Flavonoids in the Management of Diabetes and Associated Disorders;Pharmaceutical Chemistry Journal;2021-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3